From Medscape Dermatology

Coverage from the

European Academy of Dermatology and Venereology (EADV) 2022 Annual Meeting

September 07 - 10, 2022; Hybrid | Milan, Italy

September 07 - 10, 2022 Hybrid | Milan, Italy

Conference News

EADV 2022 Monkeypox Includes Mucocutaneous Involvement in Almost All Cases
MDedge News, October 4, 2022
EADV 2022 Ruxolitinib Repigments Many Vitiligo Affected Body Areas
Medscape Medical News, October 3, 2022
EADV 2022 Data Show Lebrikizumab Atopic Dermatitis Effects Maintained
Medscape Medical News, September 30, 2022
EADV 2022 BREEZE-AD-PEDS: First Data for Baricitinib in Childhood Eczema
Medscape Medical News, September 30, 2022
EADV 2022 Alopecia Areata: Positive Data Reported for Two JAK Inhibitors
Medscape Medical News, September 29, 2022
EADV 2022 Study Identifies Skin Biomarkers That Predict Newborn Eczema Risk
Medscape Medical News, September 28, 2022
EADV 2022 Apremilast Alleviates Severe Psoriasis in Some Children, Data Show
Medscape Medical News, September 19, 2022

EADV 2022 Hope Shines Bright for Hidradenitis Suppurativa Treatments
Medscape Medical News, September 16, 2022
EADV 2022 Sustained Response at 2 Years Reported for Deucravacitinib
MDedge News, September 15, 2022
EADV 2022 Anti-IgE Therapy Found Safe and Effective for Chronic Urticaria
MDedge News, September 15, 2022
EADV 2022 Roflumilast Foam Effectively Eases Seborrheic Dermatitis
Medscape Medical News, September 9, 2022
EADV 2022 Polypodium Leucotomos Found to Reverse AK Skin Damage
Medscape Medical News, September 9, 2022
EADV 2022 Dupilumab Offers 'Clinically Meaningful' Improvements in PN
Medscape Medical News, September 9, 2022
EADV 2022 Overall Survival Dips With Vitamin D Deficiency in Melanoma
Medscape Medical News, September 8, 2022

Medscape Dermatology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Psoriasis Highlights From EADV 2022
Paolo Gisondi, MD
Atopic Dermatitis Highlights From EADV 2022
Ana Maria Giménez-Arnau, MD, PhD

Popular News from EADV 2021

In AD Trial, Abrocitinib Relieves Itch Faster Than Dupilumab In a direct comparison of the oral JAK inhibitor abrocitinib to the IL-4/IL-13 inhibitor dupilumab for AD, abrocitinib offered several advantages, including faster relief of itch.
Medscape Medical News, Oct 05, 2021
First-in-Class TYK Inhibitor Shows Durable Effect for Psoriasis The 52-week data from two pivotal trials with deucravacitinib, a first-in-class inhibitor of tyrosine kinase 2 (TYK2), demonstrated durable control of moderate-to-severe plaque psoriasis.
Medscape Medical News, Oct 01, 2021
Ruxolitinib Cream Meets Endpoints in Phase 3 Vitiligo Trial A topical formulation of the JAK inhibitor ruxolitinib produced statistically significant improvement in all primary and secondary outcomes relative to vehicle alone at 24 weeks.
Medscape Medical News, Oct 04, 2021

Previous Coverage